{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:11:50Z","timestamp":1788862310991,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T00:00:00Z","timestamp":1485734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s13311-016-0511-x","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T11:28:43Z","timestamp":1485775723000},"page":"405-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease"],"prefix":"10.1016","volume":"14","author":[{"given":"Thomas N.","family":"Chase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Farlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Clarence-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-016-0511-x_bib1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.2174\/1567205012666150701103107","article-title":"Neurobiology of Alzheimer's disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions","volume":"12","author":"Raskin","year":"2015","journal-title":"Curr Alzheimer Res"},{"key":"10.1007\/s13311-016-0511-x_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer's disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-016-0511-x_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002512-200421070-00004","article-title":"Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy","volume":"21","author":"Wilkinson","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1007\/s13311-016-0511-x_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001190.pub2","article-title":"Donepezil for dementia due to Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-016-0511-x_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","article-title":"Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease","volume":"52","author":"Noetzli","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1007\/s13311-016-0511-x_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H","article-title":"Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex","volume":"48","author":"Kuhl","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-016-0511-x_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jnnp.2004.038729","article-title":"Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease","volume":"76","author":"Bohnen","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-016-0511-x_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1254\/jjp.89.7","article-title":"Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor","volume":"89","author":"Sugimoto","year":"2002","journal-title":"Jpn J Pharmacol"},{"key":"10.1007\/s13311-016-0511-x_bib9","unstructured":"Aricept (donepezil hydrochloride) prescribing information. Revised: July 2015. Eisai Inc."},{"key":"10.1007\/s13311-016-0511-x_bib10","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.clinthera.2010.06.019","article-title":"Effectiveness and tolerability of high-dose (23 mg\/d) versus standard-dose (10 mg\/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study","volume":"32","author":"Farlow","year":"2010","journal-title":"Clin Ther"},{"key":"10.1007\/s13311-016-0511-x_bib11","unstructured":"ARICEPT 23: An Unusual Dose Means More Dollars for Drug Companies. Dan C. Bolton, Mesh Medical Device Newsdesk. Feb 28, 2015."},{"key":"10.1007\/s13311-016-0511-x_bib12","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/sj.npp.1300150","article-title":"Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors","volume":"28","author":"Bontempi","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-016-0511-x_bib13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/FBP.0b013e3282da278d","article-title":"Anti-dementia drugs and hippocampal-dependent memory in rodents","volume":"18","author":"Yuede","year":"2007","journal-title":"Behav Pharmacol"},{"key":"10.1007\/s13311-016-0511-x_bib14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s002130050310","article-title":"Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys","volume":"131","author":"Rupniak","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1007\/s13311-016-0511-x_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2165\/00003088-200241100-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors","volume":"41","author":"Jann","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1007\/s13311-016-0511-x_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00019442-200407000-00003","article-title":"Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease","volume":"12","author":"Ritchie","year":"2004","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1007\/s13311-016-0511-x_bib17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/gps.1133","article-title":"Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials","volume":"19","author":"Whitehead","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1007\/s13311-016-0511-x_bib18","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00702-006-0526-2","article-title":"Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment","volume":"113","author":"Darreh-Shori","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1007\/s13311-016-0511-x_bib19","unstructured":"Chase TN, Clarence-Smith K. High dose cholinesterase inhibitor treatment of Alzheimer's disease. AAIC Abstract #2729l, 2015."},{"key":"10.1007\/s13311-016-0511-x_bib20","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/17425255.2014.915028","article-title":"Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease","volume":"10","author":"Prvulovic","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1007\/s13311-016-0511-x_bib21","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.clinthera.2006.09.017","article-title":"Solifenacin succinate for the treatment of symptoms of overactive bladder","volume":"28","author":"Maniscalco","year":"2006","journal-title":"Clin Ther"},{"key":"10.1007\/s13311-016-0511-x_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11934-005-0033-2","article-title":"The Q-T interval and antimuscarinic drugs","volume":"6","author":"Dmochowski","year":"2005","journal-title":"Curr Urol Rep"},{"key":"10.1007\/s13311-016-0511-x_bib23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11934-011-0198-9","article-title":"Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients","volume":"12","author":"Pagoria","year":"2011","journal-title":"Curr Urol Rep"},{"key":"10.1007\/s13311-016-0511-x_bib24","series-title":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"10.1007\/s13311-016-0511-x_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1007\/s13311-016-0511-x_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1007\/s13311-016-0511-x_bib27","first-page":"448","article-title":"The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy","volume":"19","author":"Mohs","year":"1983","journal-title":"Psychopharmacol Bull"},{"key":"10.1007\/s13311-016-0511-x_bib28","unstructured":"Guy W. ECDEU Assessment manual for psychopharmacology\u2014revised (DHEW Publ. No. ADM 76\u2013338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976, pp. 218\u2013222."},{"key":"10.1007\/s13311-016-0511-x_bib29","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1007\/s13311-016-0511-x_bib30","unstructured":"Amarex Clinical Research, LLC, 20201 Century Boulevard, Germantown, MD 20874."},{"key":"10.1007\/s13311-016-0511-x_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-016-0511-x_bib32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0511-x_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer's disease\u2014results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1007\/s13311-016-0511-x_bib34","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1176\/appi.ajp.160.11.2003","article-title":"Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease","volume":"160","author":"Krishnan","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s13311-016-0511-x_bib35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"LEADe Investigators. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-016-0511-x_bib36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156720511796391935","article-title":"Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two Phase 3 studies","volume":"8","author":"Harrington","year":"2011","journal-title":"Curr Alzheimer Res"},{"key":"10.1007\/s13311-016-0511-x_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3233\/JAD-150414","article-title":"Effects of the acetylcholine release agent ST101 with donepezil in Alzheimer's disease: a randomized phase 2 study","volume":"48","author":"Gauthier","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.1007\/s13311-016-0511-x_bib38","first-page":"1","article-title":"Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review","volume":"5","author":"Clegg","year":"2001","journal-title":"Health Technol Assess"},{"key":"10.1007\/s13311-016-0511-x_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/gps.1402","article-title":"A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease","volume":"21","author":"Takeda","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1007\/s13311-016-0511-x_bib40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline","volume":"148","author":"Raina","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1007\/s13311-016-0511-x_bib41","unstructured":"SAS Institute Inc., 100 SAS Campus Drive, Cary, North Carolina 27513\u20132414."},{"key":"10.1007\/s13311-016-0511-x_bib42","first-page":"422","article-title":"Acute aggravation of parkinsonism by donepezil overdose. A case report","volume":"64","author":"Nakao","year":"2006","journal-title":"Neurol Med"},{"key":"10.1007\/s13311-016-0511-x_bib43","first-page":"482","article-title":"A case of acute cholinergic adverse effects induced by donepezil overdose: a follow-up of clinical course and plasma concentration of donepezil","volume":"43","author":"Yano","year":"2003","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1007\/s13311-016-0511-x_bib44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bmj.331.7512.321","article-title":"Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials","volume":"331","author":"Kaduszkiewicz","year":"2005","journal-title":"BMJ"},{"key":"10.1007\/s13311-016-0511-x_bib45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0014-2999(96)00072-6","article-title":"An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors","volume":"30","author":"Braida","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-016-0511-x_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0166-4328(93)90130-I","article-title":"The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory","volume":"57","author":"Dawson","year":"1993","journal-title":"Behav Brain Res"},{"key":"10.1007\/s13311-016-0511-x_bib47","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/JCP.0b013e31828b5087","article-title":"Concentration of donepezil to the cognitive response in Alzheimer disease","volume":"33","author":"Yang","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl. 3","key":"10.1007\/s13311-016-0511-x_bib48","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.3233\/JAD-132639","article-title":"Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia","volume":"42","author":"Versijpt","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1007\/s13311-016-0511-x_bib49","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00002512-200825080-00007","article-title":"Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies","volume":"25","author":"Burns","year":"2008","journal-title":"Drugs Aging"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0511-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-016-0511-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0511-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:03:10Z","timestamp":1761807790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923014757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1878747923014757"],"URL":"https:\/\/doi.org\/10.1007\/s13311-016-0511-x","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-016-0511-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Author(s). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}